12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aggrastat tirofiban: Phase II started

Medicure began the open-label, U.S. Phase II SAVI-PCI trial to compare 25 µg/kg IV bolus of Aggrastat over 3 minutes followed by a shortened 0.15 µg/kg/min infusion over 1-2 hours vs. Integrilin eptifibatide infused over 12-18 hours in about 600 patients undergoing PCI. Medicure and...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >